Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucocorticoid Steroid and Alendronate Treatment Alleviates Dystrophic Phenotype with Enhanced Functional Glycosylation of α-Dystroglycan in Mouse Model of Limb-Girdle Muscular Dystrophy with FKRPP448L Mutation.

The American journal of pathology·2016
Same author

Exogenous H2S contributes to recovery of ischemic post-conditioning-induced cardioprotection by decrease of ROS level via down-regulation of NF-κB and JAK2-STAT3 pathways in the aging cardiomyocytes.

Cell & bioscience·2016
Same author

Common susceptibility variants are shared between schizophrenia and psoriasis in the Han Chinese population.

Journal of psychiatry & neuroscience : JPN·2016
Same author

Phylogenetic relationship of two popular edible Pleurotus in China, Bailinggu (P. eryngii var. tuoliensis) and Xingbaogu (P. eryngii), determined by ITS, RPB2 and EF1α sequences.

Molecular biology reports·2016
Same author

[Effect of ginsenoside total saponinon on regulation of P450 of livers of rats after γ-ray irradiation].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2016
Same author

Lipid-polymer hybrid nanoparticles for the delivery of gemcitabine.

Journal of controlled release : official journal of the Controlled Release Society·2016

Related Experiment Video

Updated: Nov 1, 2025

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.4K

Selected using bioinformatics and molecular docking analyses, PHA-793887 is effective against osteosarcoma.

Bo Wu1, Wenzhuo Yang2, Zhaoyu Fu1

  • 1Department of Orthopaedics, The First Hospital of Jilin University, Changchun, China.

Aging
|June 22, 2021
PubMed
Summary

This study identified cyclin-dependent kinase 1 (CDK1) as a prognostic target in osteosarcoma. The drug PHA-793887 showed promise in preclinical models by inhibiting CDK1, reducing tumor cell viability, and inducing apoptosis.

Keywords:
bioinformaticsbone sciencedrug treatmentosteosarcomaprognosis

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

10.3K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.9K

Related Experiment Videos

Last Updated: Nov 1, 2025

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.4K
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

10.3K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background:

  • Osteosarcoma is a primary bone cancer with limited treatment options.
  • Identifying novel prognostic and therapeutic targets is crucial for improving patient outcomes.

Purpose of the Study:

  • To identify novel prognostic and therapeutic targets for osteosarcoma.
  • To evaluate the potential of PHA-793887 as a CDK1 inhibitor for osteosarcoma treatment.

Main Methods:

  • Gene expression profiling of osteosarcoma and control tissues (GSE42352 dataset).
  • Bioinformatic analyses including Gene Ontology, KEGG, GSEA, and PPI networks.
  • In vitro assays (MTT, colony formation, scratch, flow cytometry, Western blotting, ELISA) to assess PHA-793887 efficacy.

Main Results:

  • Lower mRNA levels of CDK1 and topoisomerase II alpha correlated with better patient prognoses.
  • PHA-793887 demonstrated high binding affinity for CDK1 and reduced osteosarcoma cell viability, clonogenicity, and migration in vitro.
  • PHA-793887 induced dose-dependent apoptosis and decreased CDK1 expression in osteosarcoma cells.

Conclusions:

  • CDK1 is a potential prognostic biomarker and therapeutic target in osteosarcoma.
  • PHA-793887 exhibits preclinical efficacy against osteosarcoma by inhibiting CDK1 and warrants further investigation as a novel therapeutic agent.